Skip to content
Trial Eligibility
Menu

Breast Cancer Clinical Trials Recruiting in the US

873 studies for Breast Cancer are recruiting at 12,780 US sites, according to ClinicalTrials.gov data processed .

Breast cancer is a disease in which cells in the breast grow out of control.

Your ZIP is looked up in your browser. We don't receive or store it.

Recruiting now

Top Breast Cancer studies by number of US sites

Showing 30 studies, most US recruiting sites first.
  1. Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25

    NCT05879926

    • Phase 3
    • Ages 18 to 60 years
    • Sex: Female
    Recruiting sites
    1,085 US recruiting sites
  2. Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer

    NCT05929768

    • Phase 3
    • Ages 18 years and older
    • Sex: All
    Recruiting sites
    913 US recruiting sites
  3. Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab

    NCT05812807

    • Phase 3
    • Ages 18 years and older
    • Sex: All
    Recruiting sites
    776 US recruiting sites
  4. De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)

    NCT04852887

    • Phase 3
    • Ages 50 to 70 years
    • Sex: All
    Recruiting sites
    704 US recruiting sites
  5. Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

    NCT05334069

    • Observational
    • Ages 40 to 75 years
    • Sex: All
    • Accepts healthy volunteers
    Recruiting sites
    610 US recruiting sites
  6. ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab

    NCT06876714

    • Phase 3
    • Ages 18 years and older
    • Sex: All
    Recruiting sites
    597 US recruiting sites
  7. S1703 Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast Cancer

    NCT03723928

    • Interventional
    • Ages 18 years and older
    • Sex: All
    Recruiting sites
    585 US recruiting sites
  8. Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer

    NCT06058377

    • Phase 3
    • Ages 18 years and older
    • Sex: All
    Recruiting sites
    539 US recruiting sites
  9. Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics

    NCT06418204

    • Observational
    • Ages 18 years and older
    • Sex: All
    Recruiting sites
    482 US recruiting sites
  10. Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

    NCT05564377

    • Phase 2
    • Ages Any age
    • Sex: All
    Recruiting sites
    428 US recruiting sites
  11. E-Mindfulness Approaches for Living After Breast Cancer

    NCT06748222

    • Phase 3
    • Ages 18 to 50 years
    • Sex: All
    Recruiting sites
    372 US recruiting sites
  12. Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trial

    NCT07391774

    • Phase 3
    • Ages 18 years and older
    • Sex: All
    Recruiting sites
    201 US recruiting sites
  13. A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence

    NCT06492616

    • Phase 3
    • Ages 18 years and older
    • Sex: All
    Recruiting sites
    172 US recruiting sites
  14. S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity

    NCT03418961

    • Phase 3
    • Ages 18 years and older
    • Sex: All
    Recruiting sites
    143 US recruiting sites
  15. Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)

    NCT05633654

    • Phase 3
    • Ages 18 years and older
    • Sex: All
    Recruiting sites
    122 US recruiting sites
  16. MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression Profiles

    NCT03053193

    • Observational
    • Ages 18 years and older
    • Sex: All
    Recruiting sites
    113 US recruiting sites
  17. A Study of Sigvotatug Vedotin in Advanced Solid Tumors

    NCT04389632

    • Phase 1
    • Ages 18 years and older
    • Sex: All
    Recruiting sites
    94 US recruiting sites
  18. The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study

    NCT06377852

    • Phase 3
    • Ages 60 years and older
    • Sex: All
    Recruiting sites
    87 US recruiting sites
  19. Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)

    NCT06393374

    • Phase 3
    • Ages 18 years and older
    • Sex: All
    Recruiting sites
    84 US recruiting sites
  20. Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.

    NCT06072612

    • Phase 3
    • Ages 18 years and older
    • Sex: All
    Recruiting sites
    79 US recruiting sites
  21. ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer

    NCT07173751

    • Phase 3
    • Ages 18 years and older
    • Sex: All
    Recruiting sites
    71 US recruiting sites
  22. SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

    NCT03452774

    • Observational
    • Ages Any age
    • Sex: All
    Recruiting sites
    67 US recruiting sites
  23. A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)

    NCT06966700

    • Phase 3
    • Ages 18 years and older
    • Sex: All
    Recruiting sites
    64 US recruiting sites
  24. A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer

    NCT06790693

    • Phase 3
    • Ages 18 years and older
    • Sex: All
    Recruiting sites
    62 US recruiting sites
  25. BGB-43395 Plus Letrozole Versus CDK4/6i Plus Letrozole for Patients With Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Prior Treatment for Advanced or Metastatic Disease

    NCT07492641

    • Phase 3
    • Ages 18 years and older
    • Sex: All
    Recruiting sites
    62 US recruiting sites
  26. Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer

    NCT07085767

    • Phase 3
    • Ages 18 years and older
    • Sex: All
    Recruiting sites
    61 US recruiting sites
  27. Adding Surgery and Radiation to the Usual Treatment for HER2-Positive Breast Cancer That Had Already Spread at Diagnosis

    NCT07578116

    • Phase 3
    • Ages 18 years and older
    • Sex: All
    Recruiting sites
    59 US recruiting sites
  28. Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial

    NCT06500481

    • Phase 3
    • Ages 18 years and older
    • Sex: All
    Recruiting sites
    58 US recruiting sites
  29. EXActDNA-003 / NSABP B-64: Study of Molecular Residual Disease Detection in Breast Cancer (MRD)

    NCT06401421

    • Observational
    • Ages 18 years and older
    • Sex: All
    Recruiting sites
    53 US recruiting sites
  30. Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer

    NCT06982521

    • Phase 3
    • Ages 18 years and older
    • Sex: All
    Recruiting sites
    52 US recruiting sites

By city

Breast Cancer clinical trials by city

FAQ

Common questions

What is a clinical trial?
A clinical trial is a research study in people that tests a medical, surgical or behavioral intervention, such as an investigational drug or device. Observational studies are also listed: they collect information without assigning a treatment. Read how clinical trials work.
Is there compensation for joining a Breast Cancer clinical trial?
Compensation for time and travel may be available, but it varies by study and some studies offer none. The amount and schedule are reviewed by an ethics board and described in the consent form. See compensation in clinical trials.
How do I check if I'm eligible?
Each study lists age, sex and other inclusion and exclusion criteria on its ClinicalTrials.gov record. Only the study team can confirm eligibility, usually through a screening call or visit. Talk with your own doctor before joining any study.

Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.